044675
CAS Number
477-30-5Grade
Highly PurifiedMDL Number
MFCD00075459Molecular Formula
C21H25NO5Molecular Weight
371.4EU Commodity Code
38220090Shipping Temp
RTStorage Temp
-20°CColcemid
Anti-cancer compound. Cell synchronization agent. Used as a drug in chemotherapy by synchronizing tumor cells at metaphase, the radiosensitive stage of the cell cycle. Microtubule assembly inhibitor. Depolymerizes microtubules and limits microtubule formation (inactivates spindle fibre formation). Inhibits mitosis during cell division at metaphase by inhibiting spindle formation. Low concentrations affect microtubule dynamics and cell migration, while high concentrations promote microtubule detachment from microtubule organizing center. Apoptosis inducer and thrombopoietic agent.
Semi-synthetic from colchicine
Synonyms
Demecolcine; BRN 2822892
Molecular Formula
C21H25NO5
Method for Determining Identity
Proton NMR
Appearance
Supplied as a white to off-white powder.
Solubility
Soluble in chloroform, ethanol, or DMSO
SStorage and Stability
Store at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards
All products should be handled by qualified personnel only, trained in laboratory procedures.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Effect of colcemid on fibroblast motility: M.H. Gail & C.W. Boone; Exp. Cell Res. 65, 221 (1971)|2. Mitosis in human leukemic leukocytes during colcemid inhibition and recovery: M. McGill & B. R. Brinkley; Cancer Res. 32, 746 (1972)|3. The effects of colcemid on hematopoiesis in the mouse: P.A. Bunn Jr., et al.; J. Clin. Invest. 58, 1280 (1976)|4. Colcemid and colchicine binding to tubulin. Similarity and dissimilarity: A.C. Banerjee & B. Bhattacharyya; FEBS Lett. 99, 333 (1979)|5. Comparison of mitostatic effect, cell uptake and tubulin-binding activity on colchicine and colcemid: A.S. Serpinskaya, et al.; Biochim. Biophys. Acta 673, 86 (1981)|6. Action of demecolcine (colcemid) in the murine sarcoma 180 tumor: T. Nomura & J.E. Plager; Cancer Treat. Rep. 65, 283 (1981)|7. Colcemid effects on B16 melanoma cell progression and aberrant mitotic division: B.K. Bhuyan, et al.; J. Cell Physiol. 132, 237 (1987)|8. Colcemid and the mitotic cycle: C.L. Rieder & R.E. Palazzo; J. Cell. Sci. 102, 387 (1992)|9. Induction of apoptosis by the anti-tubulin drug colcemid: relationship of mitotic checkpoint control to the induction of apoptosis in HeLa S3 cells: S.W. Sherwood, et al.; Exp. Cell. Res. 215, 373 (1994)|10. Effects of colcemid concentration on chromosome aberration analysis in human lymphocytes: R. Kanda, et al.; J. Radiat. Res. (Tokyo) 35, 41 (1994)|11. Cell cycle arrest by Colcemid differs in human normal and tumor cells: M.N. Jha, et al.; Cancer Res. 54, 5011 (1994)|12. Dissociation of nuclear and cytoplasmic cell cycle progression by drugs employed in cell synchronization: L. Urbani, et al.; Exp. Cell. Res. 219, 159 (1995)|13. Expression of apoptosis and cell cycle related genes in proliferating and colcemid arrested cells of divergent lineage: B.W. Gallaher, et al.; Cell. Mol. Biol. 46, 79 (2000)|14. Inhibition of Cell Migration and Cell Division Correlates with Distinct Effects of Microtubule Inhibiting Drugs: H. Yang, et al.; J. Biol. Chem. 285, 32242 (2010)USBio References
No references available